FARON PHARMACEUTICALS OY

Board/Management Information • May 3, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9490W

Faron Pharmaceuticals Oy

03 May 2016

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Faron Strengthens Executive Team by Appointing New Medical Director

TURKU - FINLAND 3 May 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN) announced today that it has strengthened its Executive Management Team with the appointment of MD, PhD, eMBA Matti Karvonen as its new Medical Director. Dr. Karvonen will be responsible for overseeing Faron's drug development strategy and will play a central role in expanding the clinical programmes of Traumakine® and Clevegen®.

Dr. Markku Jalkanen, CEO of Faron said: "We are delighted to welcome Dr. Karvonen to our ambitious Executive Management Team. His appointment comes at an important time for Faron as we expand our clinical activities. Our lead drug candidate Traumakine, for the treatment of Acute Respiratory Distress Syndrome (ARDS) is now in a pan-European Phase III INTEREST trial, while clinical development for Clevegen, our novel cancer immunotherapy drug candidate is under active planning. Dr. Karvonen's experience in taking drugs through development programmes will provide an invaluable insight into the needs of both ARDS and cancer patients."

Dr. Karvonen has a background in clinical neurology with a deep medical experience in many international pharmaceutical organisations, including Roche, Biogen Idec and Novartis and has participated in many clinical programmes, most recently in the pan-European launch of a new neurological drug. In the early part of his career Dr. Karvonen held several research positions and he has also co-founded several commercial medical organisations.

For more information, please contact:

Faron Pharmaceuticals Oy

Katja Wallenlind

Phone +358 (50) 577 4807

E-mail: katja.wallenlind@faronpharmaceuticals.com

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: +44 207 862 6390

E-mail: faron@humebrophy.com

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson and Rebecca Anderson

Phone: +44 207 148 7900

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

Whitman Howard Limited, Joint Broker

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

About Faron Pharmaceuticals Ltd

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat Acute Respiratory Distress Syndrome ("ARDS"), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen®. Clevegen® is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach. Faron Pharmaceuticals is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAUUSARNAAVRUR